Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novartis MenB recombinant vaccine schedules in infants and children
2010-021528-81Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (5 arms), sponsored by Novartis. Primary endpoints: Immunogenicity after 2-dose infant primary series, Immunogenicity after 3-dose infant primary series and 1 more. Started Dec 2010; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2010-021528-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021528-81.